Deux réminiscences des Catilinaires chez Saint Jerôme et Saint Augustin

Two reminiscences from the Cicero's speeches against Catiline in the letters of St Jerome and St Augustine.

Frequency of severe pulmonary hypertension complicating "isolated" atrial septal defect in infancy.

Atrial septal defects (ASDs) are typically asymptomatic in infancy and early childhood, and elective defect closure is usually performed at ages of 4 to 6 years. Severe pulmonary hypertension (PH) complicating an ASD is seen in adulthood and has only occasionally been reported in small children. A retrospective study was undertaken to evaluate the incidence of severe PH complicating an isolated ASD and requiring early surgical correction. During a 10-year period (1996 to 2006), 355 pediatric patients underwent treatment for isolated ASDs either surgically or by catheter intervention at 2 tertiary referral centers. Two hundred ninety-seven patients had secundum ASDs, and 58 had primum ASDs with mild to moderate mitral regurgitation. Eight infants were found with isolated ASDs (6 with secundum ASDs and 2 with primum ASDs) associated with significant PH, accounting for 2.2% of all patients with ASDs at the centers. These 8 infants had invasively measured pulmonary artery pressures of 50% to 100% of systemic pressure. They were operated in the first year of life and had complicated postoperative courses requiring specific treatment for PH for up to 16 weeks postoperatively. The ultimate outcomes in all 8 infants were good, with persistent normalization of pulmonary pressures during midterm follow-up of up to 60 months (median 28). All other patients with ASDs had normal pulmonary pressures, and the mean age at defect closure was significantly older, at 6.2 years for secundum ASDs and 3.2 years for primum ASDs. In conclusion, ASDs were rarely associated with significant PH in infancy but then required early surgery and were associated with excellent midterm outcomes in these patients.

Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk.

Context: Subclinical thyroid dysfunction is common in older people. However, its clinical importance is uncertain. Objective: Our objective was to determine the extent to which subclinical hyperthyroidism and hypothyroidism influence the risk of heart failure and cardiovascular diseases in older people. Setting and Design: The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) is an prospective cohort study. Patients: Patients included men and women aged 70-82 yr (n = 5316) with known cardiovascular risk factors or previous cardiovascular disease. Main Outcome Measures: Incidence rate of heart failure hospitalization, atrial fibrillation, and cardiovascular events and mortality according to baseline thyroid status were evaluated. Euthyroid participants (TSH =0.45-4.5 mIU/liter) were compared with those with subclinical hyperthyroidism (TSH <0.45 mIU/liter) and those with subclinical hypothyroidism (TSH ≥4.5 mIU/liter, both with normal free T(4)). Results: Subclinical hyperthyroidism was present in 71 participants and subclinical hypothyroidism in 199 participants. Over 3.2 yr follow-up, the rate of heart failure was higher for subclinical hyperthyroidism compared with euthyroidism [age- and sex-adjusted hazard ratio (HR) = 2.93, 95% confidence interval (CI) = 1.37-6.24, P = 0.005; multivariate-adjusted HR = 3.27, 95% CI = 1.52-7.02, P = 0.002). Subclinical hypothyroidism (only at threshold >10 mIU/liter) was associated with heart failure (age- and sex-adjusted HR = 3.01, 95% CI = 1.12-8.11, P = 0.029; multivariate HR = 2.28, 95% CI = 0.84-6.23). There were no strong evidence of an association between subclinical thyroid dysfunction and cardiovascular events or mortality, except in those with TSH below 0.1 or over 10 mIU/liter and not taking pravastatin. Conclusion: Older people at high cardiovascular risk with low or very high TSH along with normal free T(4) appear at increased risk of incident heart failure.

Soil-Cement Stabilization, Part 1, Materials and Construction, HR-75, 1962

This report covers the construction in 1961 of the soil-cement base and related pavement structure on Iowa 37 from Soldier to Dunlap, (F-861(6), Crawford, Harrison, Monona). The report also contains an account of the experimental work performed on the same road under research project HR-75.

Caracterització energètica del parc edificatori anterior al codi Tècnic de l’edificació CTE

En l'actualitat, l'eficiència energètica en l'edificació és un dels conceptes més importants, notan sols per la política energètica Espanyola, sinó també Europea amb un objectiu d'estalvidel 20% el 2020. Dins el sector de l'edificació, les normatives sobre eficiència energèticas'incorporen a partir de la transposició de les directives europees 2002/91 i 2010/31, queobliga, entre d'altres, a la certificació energètica, no només d'edificis nous, sinó també delsedificis antics que es trobin en situació de lloguer o compra/venta. L'objecte del present projecte és fer un catàleg de solucions constructives típiques, que esdonen abans de l'aprovació i entrada en vigor del CTE a partir del RD 314/2006. El catàlegconsta de variacions en l'evolvent de l'edifici, variacions en la contribució solar i variacionsen les instal•lacions de climatització. Cadascuna d'aquestes combinacions s'analitzarà ambels programaris LIDER i CALENER, de forma que s'obtindrà una estimació de les emissionsde CO2 per a cada cas, i a partir del projecte de real decret de certificació d'edificis existents(encara en tramitació a data de redacció del full de projecte d'aquest projecte), s'assignaràuna qualificació energètica. D'aquesta manera, es podrà tenir una primera aproximació de laqualificació energètica dels edificis existents, a partir de les seves característiques.Pel que fa a les especificacions, es definirà un edifici unifamiliar aïllat, s'establiran un conjuntd'evolvents, s'especificaran quins espais de l'edifici són habitables i quins no, i es definiranun conjunt d'instal•lacions.L'abast de l'estudi comprendrà els edificis situats a la zona climàtica C2 de la província deGirona. Aquesta zona inclou els edificis que es troben a una alçada del nivell del mar deentre 0 m a 342 m (dins la província de Girona)

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

BACKGROUND: Most patients with glioblastoma are older than 60 years, but treatment guidelines are based on trials in patients aged only up to 70 years. We did a randomised trial to assess the optimum palliative treatment in patients aged 60 years and older with glioblastoma. METHODS: Patients with newly diagnosed glioblastoma were recruited from Austria, Denmark, France, Norway, Sweden, Switzerland, and Turkey. They were assigned by a computer-generated randomisation schedule, stratified by centre, to receive temozolomide (200 mg/m(2) on days 1-5 of every 28 days for up to six cycles), hypofractionated radiotherapy (34·0 Gy administered in 3·4 Gy fractions over 2 weeks), or standard radiotherapy (60·0 Gy administered in 2·0 Gy fractions over 6 weeks). Patients and study staff were aware of treatment assignment. The primary endpoint was overall survival. Analyses were done by intention to treat. This trial is registered, number ISRCTN81470623. FINDINGS: 342 patients were enrolled, of whom 291 were randomised across three treatment groups (temozolomide n=93, hypofractionated radiotherapy n=98, standard radiotherapy n=100) and 51 of whom were randomised across only two groups (temozolomide n=26, hypofractionated radiotherapy n=25). In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (8·3 months [95% CI 7·1-9·5; n=93] vs 6·0 months [95% CI 5·1-6·8; n=100], hazard ratio [HR] 0·70; 95% CI 0·52-0·93, p=0·01), but not with hypofractionated radiotherapy (7·5 months [6·5-8·6; n=98], HR 0·85 [0·64-1·12], p=0·24). For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (8·4 months [7·3-9·4; n=119] vs 7·4 months [6·4-8·4; n=123]; HR 0·82, 95% CI 0·63-1·06; p=0·12). For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 0·35 [0·21-0·56], p<0·0001; HR for hypofractionated vs standard radiotherapy 0·59 [95% CI 0·37-0·93], p=0·02). Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (9·7 months [95% CI 8·0-11·4] vs 6·8 months [5·9-7·7]; HR 0·56 [95% CI 0·34-0·93], p=0·02), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 0·97 [95% CI 0·69-1·38]; p=0·81). As expected, the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18). Grade 3-5 infections in all randomisation groups were reported in 18 patients. Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed. INTERPRETATION: Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years. Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma. MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide. FUNDING: Merck, Lion's Cancer Research Foundation, University of Umeå, and the Swedish Cancer Society.

Le Mari de Lucie. Le Soulier de Rosine. Par Mme Manoël de Grandfort

Comprend : Le soulier de Rosine

Iowa Department of Transportation Major Items - Preliminary Quantity Report, January 20, 2016; With Addendums

Weekly letting report

2009 Calendar Year Annual Report of the Watershed Improvement Review Board

The Board, codified in Chapter 466A, is an independent, self-governing body directed to award grants for water quality improvement and flood prevention in the state. The Board is authorized to request applications from soil and water conservation districts, local watershed improvement committees, public water supply utilities, counties, county conservation boards and cities and award grants to these entities. These grants are issued from the Watershed Improvement Fund. Annual appropriations of $5 million plus interest earned on the Watershed Improvement Fund allowed the Board to issue two Request For Applications in 2009. On February 27, the Board awarded grants to seven applicants for a total of $2,366,861. On September 21, the Board awarded grants to thirteen applicants for a total of $5,120,832. In addition to providing environmental benefits, these implementation projects stimulate economic recovery and create jobs through the purchasing oflocal goods and services.

[Pérouse. Rocca Paolina, Porta Marzia]

Référence bibliographique : Weigert, 342

2015 Calendar Year Annual Report of the Watershed Improvement Review Board

The Watershed Improvement Fund and the Iowa Watershed Improvement Review Board (WIRB) were created in 2005. This statute is now codified in Iowa Code Chapter 466A. The fifteen-member Board conducted seven meetings throughout the year in-person or via teleconference. Meetings were held January 23, February 27, April 17, June 18, July 24, September 25 and December 17. Attachment 1 lists the board members and their organization affiliation. The Board completed one Request For Applications (RFA) for the Watershed Improvement Fund. The RFA was announced November 6, 2014 and closed December 29, 2014. December 29, 2014 Closing Date Request For Applications: The Board received 16 applications in response to this RFA. These applications requested $2.8 million in Watershed Improvement Funds and leveraged an additional $9.1 million for a total of $11.9 million of watershed project activity proposed. After reviewing and ranking the applications individually from this RFA, the Board met and selected eight applications for funding. The eight applications were approved for $1,249,861 of Watershed Improvement Funds. Data on the eight selected projects in this RFA include the following: • These projects included portions of 12 counties. • The $1.2 million requested of Watershed Improvement Funds leveraged an additional $4.2 million for a total of $5.4 million in watershed improvements. • Approved projects ranged in funding from $41,980 to $250,000. Attachment 2 lists the approved projects’ name, applicant name, project length, county or counties where located, and funding amount for the RFA. Attachment 3 is a map showing the status of all projects funded since inception of the program. At the end of 2015 there are 111 completed projects and 39 active projects. In cooperation with the Treasurer of State, the WIRB submitted the 2015 year-end report for the Rebuild Iowa Infrastructure Fund to the Legislative Services Agency and the Department of Management. Attachment 4 contains the 2015 annual progress reports submitted from active projects or projects finished in 2015.